HW
CORT icon

Hancock Whitney’s Corcept Therapeutics CORT Stock Holding History

Hancock Whitney’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,806
Closed -$503K – 764
2026
Q1 		$503K Buy
10,806
+3,312
+44% +$124K 0.01% 567
2025
Q4 		$261K Sell
7,494
-14
-0.2% -$1.1K ﹤0.01% 697
2025
Q3 		$624K Sell
7,508
-86
-1% -$6.22K 0.01% 522
2025
Q2 		$557K Sell
7,594
-9,964
-57% -$722K 0.01% 540
2025
Q1 		$2.01M Sell
17,558
-663
-4% -$40.4K 0.07% 207
2024
Q4 		$918K Sell
18,221
-4,733
-21% -$248K 0.03% 326
2024
Q3 		$1.06M Buy
22,954
+270
+1% +$9.59K 0.03% 305
2024
Q2 		$737K Sell
22,684
-4,813
-18% -$132K 0.03% 348
2024
Q1 		$693K Buy
27,497
+15,567
+130% +$368K 0.02% 367
2023
Q4 		$387K Sell
11,930
-18
-0.2% -$494 0.01% 490
2023
Q3 		$326K Sell
11,948
-432
-3% -$12.5K 0.01% 514
2023
Q2 		$275K Sell
12,380
-5,092
-29% -$117K 0.01% 550
2023
Q1 		$378K Sell
17,472
-2,564
-13% -$56.2K 0.02% 487
2022
Q4 		$407K Sell
20,036
-75
-0.4% -$1.88K 0.02% 470
2022
Q3 		$516K Sell
20,111
-467
-2% -$12.5K 0.02% 410
2022
Q2 		$489K Sell
20,578
-789
-4% -$17.2K 0.02% 424
2022
Q1 		$481K Sell
21,367
-4,366
-17% -$92.9K 0.02% 477
2021
Q4 		$510K Sell
25,733
-203
-0.8% -$4.12K 0.02% 480
2021
Q3 		$510K Sell
25,936
-93
-0.4% -$1.95K 0.02% 471
2021
Q2 		$573K Sell
26,029
-7,755
-23% -$173K 0.02% 521
2021
Q1 		$803K Sell
33,784
-484
-1% -$12.9K 0.03% 449
2020
Q4 		$897K Sell
34,268
-197
-0.6% -$4.15K 0.03% 403
2020
Q3 		$599K Sell
34,465
-171
-0.5% -$2.73K 0.02% 472
2020
Q2 		$583K Sell
34,636
-4,241
-11% -$59.6K 0.02% 482
2020
Q1 		$462K Buy
38,877
+11,117
+40% +$138K 0.02% 526
2019
Q4 		$336K Sell
27,760
-14,760
-35% -$205K 0.01% 651
2019
Q3 		$601K Sell
42,520
-5,902
-12% -$72.5K 0.02% 543
2019
Q2 		$540K Buy
+48,422
New +$540K 0.02% 603

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hancock Whitney's CORT Position: Q2 2026 in Review

Hancock Whitney sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 10,806 shares — an estimated $503K sold.

Hancock Whitney first reported a position in CORT in Q2 2019 and held it in 28 quarters. The position peaked at $2.01M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Hancock Whitney reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hancock Whitney sold 10,806 Corcept Therapeutics shares in Q2 2026, an estimated $503K.
  • Hancock Whitney first reported a position in Corcept Therapeutics in Q2 2019 and held it in 28 quarters.
  • Hancock Whitney's Corcept Therapeutics position peaked at $2.01M in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Hancock Whitney's 13F filing for Q2 2026, filed 14 Aug 2026.